DRAXXIN® (tulathromycin) Injectable Solution from Pfizer Animal Health is now approved by the US Center for Veterinary Medicine and the Food and Drug Administration for the control of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

"This new claim will help swine producers to better control respiratory disease," says Steve Sornsen, DVM, MS, director of veterinary services for Pfizer Animal Health. "DRAXXIN is rapidly released and absorbed from the injection site and extensively distributed, so the product acts quickly against respiratory disease. Furthermore, DRAXXIN provides high and long-lasting concentrations in the lung tissues providing a complete treatment and excellent efficacy treating and controlling swine respiratory disease."

It has been proven that DRAXXIN provides an extended clinical duration of activity in pigs of at least nine days after a single intramuscular dose. "A single dose of DRAXXIN ensures instant compliance, fast and long-lasting therapy," Dr Sornsen continues. "Producers don’t have to worry about the additional labor cost of giving multiple injections as with other conventional products. Also, there is added benefit of handling sick animals only once to reduce their stress and speed recovery."

DRAXXIN is indicated for the treatment of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis and Mycoplasma hyopneumoniae, all five key bacterial respiratory pathogens. The product requires a low-volume dose and is available in 50, 100, 250 and 500 mL sizes.

For more information about the proper use of DRAXXIN in swine operations, producers should talk with their veterinarian or local Pfizer Animal Health representative, or visit www.draxxin.com.

Further Reading

-

Find out more information on the diseases mentioned here by clicking here.